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OBJECTIVE: The aim of this study was to simultaneously monitoring cytomegalovirus and human herpesvirus 6 active
infections using nested-polymerase chain reaction and, together with clinical findings, follow the clinical status of
patients undergoing liver transplant.
INTRODUCTION: The human b-herpesviruses, including cytomegalovirus and human herpesvirus 6, are ubiquitous
among human populations. Active infections of human herpesvirus 6 and cytomegalovirus are common after liver
transplantation, possibly induced and facilitated by allograft rejection and immunosuppressive therapy. Both
viruses affect the success of the transplant procedure.
METHODS: Thirty patients submitted to liver transplant at the Liver Transplant Unit, at the Gastro Center, State
University of Campinas, SP, Brazil, were studied prospectively from six months to one year, nested-polymerase chain
reaction for cytomegalovirus and human herpesvirus 6 DNA detections. Two or more consecutive positive nested-
polymerase chain reaction were considered indicative of active infection.
RESULTS: Active infection by cytomegalovirus was detected in 13/30 (43.3%) patients, median time to first
cytomegalovirus detection was 29 days after transplantation (range: 0-99 days). Active infection by human
herpesvirus 6 was detected in 12/30 (40%) patients, median time to first human herpesvirus 6 detection was 23.5
days after transplantation (range: 0-273 days). The time-related appearance of each virus was not statistically
different (p= 0.49). Rejection of the transplanted liver was observed in 16.7% (5/30) of the patients. The present
analysis showed that human herpesvirus 6 and/or cytomegalovirus active infections were frequent in liver transplant
recipients at our center.
CONCLUSIONS: Few patients remain free of betaherpesviruses after liver transplantation. Most patients presenting
active infection with more than one virus were infected sequentially and not concurrently. Nested-polymerase chain
reaction can be considered of limited value for clinically monitoring cytomegalovirus and human herpesvirus 6.
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INTRODUCTION
The human b-herpesviruses, including cytomegalovirus
(CMV) and human herpesvirus 6 (HHV-6), are ubiquitous
among human populations.1 In Brazil, serological prevalence
surveys conducted in the North and Southeast regions show
adult infections rates for HHV-6 and CMV of around 90%
among the population studied (0-40 years of age), with the
primary infection occurring during the first year of life.2-4 Both
viral agents can cause several human diseases either as a
consequence of reinfection or reactivation of latent infection.5-7
The reactivation of latent HHV-6 and CMV is common
following liver transplantation. The reactivation may possibly
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be induced and facilitated by allograft rejection and immuno-
suppressive therapy.8,9 Both viruses affect the success of the
transplant procedure. Viral infection is associated with several
observable clinical findings: fever, neutropenia, central nervous
system manifestations or other visceral involvements.10 In
addition, HHV-6 viremia is an independent significant
predictor of invasive fungal infections and is associated with
late mortality in liver transplantation recipients.11 In addition,
coinfection with the viral agents can lead to a higher frequency
of transplant rejection.12,13 The diagnosis of recrudescence or
new infection with CMV and HHV-6 is not easy. Although
serological detection techniques are available, the diagnostic
value of a positive result is limited by the high prevalence of
infection in adults.2,3 A report of specific anti-CMV or HHV-6
IgM in the sera or a four-fold rise in IgG antibodies can be used
as a diagnostic criterion, but such an assay has limited
sensitivity. Moreover, the interpretation of serological results
is complicated by the fact that both primary and secondary
infections with other herpes viruses may be associated with a
concurrent antibody response to HHV-6.6,14 Amplification
techniques are also available for the diagnosis of both viral
agents; however, the results obtained using these techniques
can be controversial, as they are dependent on the method of
PCR employed.15-17 Nested PCR (N-PCR) amplifies one DNA
target-specific sequence and is divided into two stages. In the
first stage, a pair of primers amplifies the specific sequence of
DNA. In the second, a new primer set is used for an internal
region of the previously amplified fragment. In this second
stage, the DNA is maintained at a high concentration to
prevent nonspecific annealing, thus making this technique
more efficient and specific.18,19 The aim of this study was to
simultaneously monitor CMV and HHV-6 active infections
using nested PCR and, together with clinical findings gathered
over periods of sixmonths to one year, follow the clinical status
of patients undergoing liver transplants. CMV and HHV-6
antigenemia were also compared with the nested PCR results.
PATIENTS AND METHODS
Patients - Thirty patients submitted for liver transplanta-
tion at the Liver Transplant Unit, Gastro Center in the State
University of Campinas, SP, Brazil were studied prospec-
tively for a period of six months to one year using N-PCR
for CMV and HHV-6 DNA detection. For basic immuno-
suppressive therapy, the patients received steroids,
azathioprine and cyclosporine. Tacrolimus (FK 506) and
mycophenolate mofetyl (MMF) were prescribed based on
selected patient characteristics and specific protocol studies.
High doses of methyl prednisone were used as an anti-
rejection treatment. All liver transplant recipients received
200 mg of acyclovir every 12 h for 60 days for prophylaxis
against Herpes simplex infection because of the high
seroprevalence of this virus in the Brazilian population
(data not reported). Each patient protocol was revised and
checked for clinical findings associated with infection by
CMV or HHV-6. All episodes of rejection were documented
by liver biopsy. Routine prophylaxis for CMV infection was
not used unless the donor was positive and the recipient
serum negative for CMV. Ganciclovir was administered for
two weeks for protection against CMV in patients with two
or more consecutive positive PCR results.20 No patients
received anti-HHV-6 therapy during this study. Informed
consent was obtained from each enrolled patient. The study
protocol was approved by the Ethics Committee of the
School of Medical Science at the State University of
Campinas. All clinical and laboratory records were
reviewed for evidence of HHV-6 and CMV-attributable
disease symptoms.
Collection of blood samples - Peripheral blood samples
were drawn weekly in the first month post-transplant. At
thirty to 90 days post-transplantation, blood samples were
collected every two weeks. After 90 days, samples were
collected monthly up to one year post-transplant.
Peripheral blood leukocyte DNA extraction – The
procedures for isolating blood leukocytes and DNA extrac-
tion for CMV have been described previously.14,21 The DNA
amount and purity were determined by optical density
readings obtained using spectrophotometry and by rea-
ding the absorbance at a wavelength of 260 nm
(1 OD=50 ng). The final DNA concentration present in
each sample was determined by the formula OD
2606506factor of dilution =ng/ml.
Serum DNA extraction - DNA was extracted from 200 mL
of serum using a phenol-chloroform protocol after treatment
with lysis buffer containing SDS and overnight incubation
with proteinase K at 65 C˚, followed by DNA precipitation
with cold ethanol. The resulting DNA pellet was eluted in
50 mL of TE buffer (Tris EDTA).22
CMV Nested PCR - Five microliters of DNA extracted
from PBL, as described above, was used in the nested PCR.
The reaction mixture contained primers specific to CMV
and was generated following a previously described
protocol.15,16 To exclude false-negative results, the DNA
samples were subjected to PCR with b-globin primers.23
HHV-6 Nested PCR– Nested PCR was carried out using
5 mL of DNA extracted from serum as described above. The
primers and protocol used for HHV-6 nested PCR have
been previously described.24
All amplifications were carried out on a Robocycler 40
(Stratagene, La Jolla, CA, USA). The nested PCR products
were analyzed under UV light after electrophoresis in 2%
agarose (Gibco-BRL) and staining of the gel with ethidium
bromide. All nested PCR reactions were carried out in
duplicate using a second fresh aliquot.
CMV pp65-antigenemia- Blood samples were collected in
EDTA-containing tubes and transferred to the laboratory
within 6 hours. Leukocytes were isolated by a dextran
sedimentation method that was followed by erythrocyte
lysis. The cell pellet was suspended in phosphate-buffered
saline (PBS), and the polymorphonuclear leukocytes (PML)
were then centrifuged to prepare cytospin slides (36105
PML per slide). The slides were air-dried and fixed in
formaldehyde before being immunostained with monoclo-
nal antibodies (Iq Products, Netherlands) and incubated
with a peroxidase-labeled anti-mouse secondary antibody
(HRP, Biotest, Dreieich, Germany). The test was carried out
in duplicate, and the results were expressed as the number
of positive cells per 36105 PML.25-27
HHV-6 specific antigens in peripheral blood mono-
nuclear cells (PBMCs)- The presence of the HHV-6 specific
antigens in the PBMC cytopreparations was demonstrated
by indirect immunoperoxidase staining using monoclonal
antibodies against both the A and B variants (MAB8533 and
MAB8535, Chemicon, Inc., Temecula, CA). Normal mouse
IgG was used as a negative control for non-specific binding.
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A peroxidase-conjugated anti-mouse antibody (Dako,
Copenhagen, Denmark) and a peroxidase-conjugated goat
anti-rabbit antibody (Zymed, San Francisco, CA) were used
as the second and third antibodies. A 3-amino-9-ethyl
carbazole solution containing hydrogen peroxide was used
as a stain. Mayer’s hematoxylin was used for counter-
staining.28,29
Definitions- Active CMV infection was defined as two or
more consecutive N-PCR positive results and/or one
positive pp65-antigenemia.5,26,30-32 CMV disease infection
was determined based on biopsy and symptoms consistent
with CMV disease including fever, malaise, myalgia,
anorexia and leucopenia accompanied by active CMV
infection.5,30 Patients were considered to have CMV viral
syndrome if they suffered from unexplained fever (.37.5 C˚)
for at least 3 days, in combination with at least one of the
following features: arthralgia, leukopenia (,36109/l),
thrombocytopenia (,1506109/l) and liver enzyme elevation
(ALT.50 U/l).33 A patient was considered to have asymp-
tomatic CMV infection when active CMV infection occurred
without the signs, symptoms, or laboratory abnormalities
described above. A patient was considered to have an active
HHV-6 infection based on one N-PCR positive result from
serum-extracted DNA.
Statistical analysis- Categorical variables were compared
using a Fisher’s exact test or a chi-squared test. The Mann-
Whitney-U test was used to compare continuous variables.
p,0.05 was considered statistically significant.
Figure 1 - Electrophoresis: A-N-PCR-amplified HCMV DNA of 4 peripheral blood samples (159 bp). B-N-PCR-amplified HHV-6 DNA of 5
peripheral blood samples. Agarose gel 2% ethidium bromide staining and photographed under UV light. M= molecular weight
standard (Ladder 100 bp). C+ = positive control; C– = negative control; B = water.
Table 1 - Clinical and laboratory findings, day of onset and N-PCR for HCMV or HHV-6 in liver transplantation patients.
Pt# Clinical and Laboratory Findings Onseta Active Infections (
aday) by N-PCR Disease
HCMV HHV-6 Co-infection
1 Absent - +(91) - - No
2 Absent - +(66) +(87) + No
3b Fever, granulocytopenia 76 +(181) - - Yes
4 Granulocytopenia, thrombocytopenia 19 +(19) - - Yes
5b Granulocytopenia, thrombocytopenia, diarrhea 21 +(20) - - Yes
6b Fever, diarrhea 93 +(7) +(300) + Yes
7{.b Fever, thrombocytopenia, granulocytopenia, 127 - - - No
8 Granulocytopenia, thrombocytopenia, diarrhea,
fever, mucosal ulcers
30 +(25) - - Yes
9 Diarrhea, poliatralgia, myalgia, liver abscesses,
colonic ulcers
45 - - - No
10 Absent - +(18) - - No
11 Fever, encephalitis 24 - +(12) - Yes
12 Diarrhea - - - - No
13b Diarrhea 26 - - - No
14{ Absent - - +(98) - No
15{ Fever, granulocytopenia 84 +(62) +(62) + Yes
16 Absent - - - - No
17 Absent - - +(47) - No
18 Absent - - +(6) - No
19{ Absent - - - - No
20{ Absent - - +(34) - No
21{ Thrombocytopenia, encephalopathy, fever 9 - +(12) - Yes
22 Absent - - - - No
23 Absent - - - - No
24 Fever, headache 25 +(26) +(32) + Yes
25{ Granulocytopenia, thrombocytopenia - - +(77) - Yes
26 Granulocytopenia, thrombocytopenia - +(92) - - Yes
27 Absent - +(114) - - No
28 Thrombocytopenia, encephalopathy 15 +(51) - - Yes
29 Absent - - - - No
30 Absent - - +(51) - No
Pt# = patient numbers; aday = post-transplant; brejection; {death.
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RESULTS
The nested PCR for CMV and HHV-6 was standardized
with positive and negative DNA controls for each virus.
Figure 1 illustrates the nested PCR products from CMV and
HHV-6 positive and negative samples. Active infection of
CMV was detected in 13/30 (43.3%) patients. The median
time to initial CMV detection was 29 days following
transplantation (range: 0-99 days). Active infection of
HHV-6 was detected in 12/30 (40%) patients. The median
time to initial HHV-6 detection was 23.5 days after
transplantation (range: 0-273 days). The time to detection
of each virus was not statistically different (p = 0.49). Co-
infection did not occur frequently (Table 1), and CMV and/
or HHV-6 DNA detection prior to positive CMV-pp65
antigenemia was observed in most patients.
Overall, 53.3% (16/30) of patients presented viral infec-
tion-related symptoms and/or laboratory findings such as
fever, granulocytopenia, thrombocytopenia, diarrhea, oral
or intestinal ulcers and encephalitis (Table 1). Twenty
percent (6/30) of patients had detectable CMV DNA and/
or HHV-6 DNA in their serum associated with other
laboratory and/or clinical manifestations of infection.
Several cases demonstrated clinical manifestation, and
CMV and/or HHV-6 active infection also were observed,
but not concomitantly.
The rejection of the transplanted liver was observed in
16.7% (5/30) of the patients, although the time of the
rejection episodes was not correlated to CMV and HHV-6
active infection (p.0.05) (Table 2). Most patients were
successfully treated with steroids.
The mortality rate at the one-year follow-up was 23% (7/
30) (Table 3), and HHV-6 was detected in several cases.
However, the deaths could not be correlated with active
infections caused by either virus (p . 0.05).
DISCUSSION
The results of the present study indicate that HHV-6 and/
or CMV infections were frequent in liver transplant
recipients in the Gastro Center Hepatic Transplant Unit at
the State University of Campinas (Campinas/Sao Paulo/
Brazil). CMV and/or HHV-6 DNAemia was found in the
majority of patients during the one year follow-up period.
Our results are in agreement with the results of prior
studies.9,34 These other studies suggest that the HHV-6 virus
does not cause disease in itself but acts as a co-adjuvant to
facilitate the emergence of several pathogens such as
CMV.6,17,35 In the cohort studied, CMV and HHV-6 active
infection data were in agreement with these reports. As
there was no predominance of either type of viral infection,
it was not possible to observe HHV-6 facilitation activity.
The lack of predominance was probably because of the
small sample number enrolled in this study (n= 30).
Qualitative PCR, such as nested PCR, cannot distinguish
between low and high viral load, and this may have
contributed to the difficulty in determining significant
viremia. However, in our center, N-PCR detected CMV
DNA in two or more consecutive samples. These results had
a considerable correlation with antigenemia testing (data
not shown). N-PCR carried out with DNA extracted from
serum is also frequently unable to detect latent infection.
Previous studies have noted the presence of CMV specific
antigens in renal allograft biopsy material together with
acute or chronic rejection, suggesting an association
between viral infection and rejection.36 In the present study,
this association could not be found because only one patient
presented active infection by both agents, and HHV-6
DNAemia was not found during follow-up in any of the
cases. In addition, the evaluation period of this study was
not long enough to exclude the possibility that rejection may
occur in patients co-infected after a time greater than one
year. Active HHV-6 infection was observed in most of the
patients who died after the one year follow-up, but this
finding was not time-related.
CONCLUSION
The results presented herein indicate that few patients
remain free of b-herpesviruses following liver transplanta-
tion. Most patients with an active infection by more than
one virus were infected sequentially and not concurrently.
Active infections with HHV-6 or CMV might develop
independently of each other. Most patients with HHV-6
active infections were asymptomatic, although several cases
of HHV-6 active infection occurred among patients who
died post-transplantation. Nested PCR is of limited value as
a clinical CMV and HHV-6 monitoring tool.
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Table 2 - Patients who presented at least one episode of
rejection during follow-up and episodes of CMV and/or
HHV-6 active infection.
Patient CMV HHV-6 Grade of rejection
3 - - Mild (104)
5 +(20) - Moderate (493)
6 +(7) +(300) Mild (283)
7 - - Mild (105)
13 - - Moderate (85)
*Numbers between parentheses represent day of onset.
Table 3 - Cause of patient death and episodes of CMV
and/or HHV-6 active infection.
Patient CMV HHV-6 Cause of death
7 - - Gastrointestinal
bleeding (178)
14 - +(98) Sepsis (293)
15 +(62) +(62) Sepsis (140)
19 - - Multiple organ
failure (27)
20 - +(34) Sepsis (54)
21 - +(12) Graft failure (84)
25 - +(77) Base disease
relapsed (98)
*Numbers between parentheses represent day of onset.
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